BEGIN:VCARD VERSION:3.0 FN;CHARSET=UTF-8:Jeffrey R Curtis N;CHARSET=UTF-8:Curtis;Jeffrey;R;; PROFILE:VCARD ADR;CHARSET=UTF-8;TYPE=WORK:;FOT 802D;510 20th Street South;Birmingham;AL;3 5294;USA TEL;CHARSET=UTF-8;TYPE=WORK,VOICE:205-975-2176 EMAIL;CHARSET=UTF-8;TYPE=WORK,INTERNET:jcurtis@uab.edu TZ:-0400 GEO:33.507556000000;-86.809324000000 TITLE;CHARSET=UTF-8:Associate Professor of Medicine ORG;CHARSET=UTF-8:University of Alabama at Birmingham;Clinical Immunology/R heumatology CATEGORIES;CHARSET=UTF-8:CANRAD Network Member NOTE;CHARSET=UTF-8:Dr. Jeffrey Curtis is an Associate Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorder s\, which has a major emphasis on evaluating the safety and comparative eff ectiveness of medications for rheumatic diseases. Additionally\, as the Dir ector of the UAB Arthritis Clinical Intervention Program\, he leads the cli nical trials unit for the rheumatology division at UAB\, with a particular focus on rheumatoid arthritis (RA). He is the Co-Director of the UAB Pharma coepidemiology and Pharmacoeconomics Research (PEER) Unit. He also is an As sociate Scientist for the UAB Center of Metabolic Bone Disease.\r\nDr. Curt is received a Medical Degree (MD) and a Master of Public Health (MPH) degre e from Oregon Health &\; Sciences University in Portland. He subsequentl y completed a residency in internal medicine at Oregon Health &\; Scienc e University and a fellowship in rheumatology at UAB. He received his Maste r of Science (MS) degree in epidemiology at the Harvard School of Public He alth. He is board-certified in rheumatology.\r\n The evaluation of the eff icacy\, comparative effectiveness\, and safety of the medications used to t reat rheumatoid arthritis and other forms of inflammatory arthritis are amo ng Dr. Curtis’s research interests. He served on the Core Expert Panel fo r the ACR’s 2008 and 2012 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He currently is the D eputy Director for a collaborative project between the FDA\, the Agency for Healthcare Research and Quality (AHRQ)\, and a number of academic centers studying the safety of biologic agents using multiple\, pooled national dat a sources.\r\n Dr. Curtis also studies risk factors for and outcomes of os teoporosis\, particularly among men and non-Caucasians. He was a member of the ACR’s task force to update recommendations for the management of gluc ocorticoid induced osteoporosis (GIOP). He also served on the ASBMR Task Fo rce on Atypical Subtrochanteric and Diaphyseal Fractures.\r\n Dr. Curtis i s a member of the American College of Rheumatology (ACR)\, the Internationa l Society for Pharmacoepidemiology (ISPE)\, and the American Society of Bon e and Mineral Research (ASBMR). He has authored more than 150 peer-reviewed articles and book chapters. He is on the editorial board for Pharmacoepide miology and Drug Safety (PDS) and Arthritis Care and Research (AC&\;R). PRODID:-//Connections Business Directory for WordPress//Version 2.0//EN CLASS:PUBLIC SORT-STRING:Curtis END:VCARD